Bayraktar Soley, Morency Belline, Escalón Maricer P
Department of Hematology/Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
BMJ Case Rep. 2010 Oct 21;2010:bcr0520102975. doi: 10.1136/bcr.05.2010.2975.
We report a case of a 25-year-old woman with chronic myeloid leukaemia who was randomised to dasatinib 100 mg orally daily in a clinical trial. The patient was advised to avoid pregnancy while on treatment due to its teratogenic potential. Five months later, the patient was found to be 6 weeks pregnant. Once pregnancy was confirmed, dasatinib was immediately stopped and the patient was taken off the trial. She was managed conservatively during the remainder of her pregnancy with close observation only. She delivered a healthy infant at 37 weeks' gestation without any documented birth defects. Dasatinib has been shown in animal studies to cause fetal toxicities, but the effect of exposure during conception and pregnancy in humans is not known. We provide a full report of a successful pregnancy in a patient who was exposed to dasatinib during the first trimester; we also give a brief literature review.
我们报告了一例25岁的慢性髓性白血病女性患者，该患者在一项临床试验中被随机分配接受每日口服100毫克达沙替尼的治疗。由于其致畸潜力，患者在治疗期间被建议避免怀孕。五个月后，该患者被发现已怀孕6周。一旦确认怀孕，达沙替尼立即停药，患者退出试验。在其剩余孕期中，她仅通过密切观察进行保守处理。她在妊娠37周时分娩了一名健康婴儿，没有任何记录在案的出生缺陷。动物研究表明达沙替尼会导致胎儿毒性，但在人类受孕和怀孕期间接触达沙替尼的影响尚不清楚。我们提供了一份关于一名在孕早期接触达沙替尼的患者成功妊娠的完整报告；我们还进行了简要的文献综述。
